Table 2.
Predictive risk for restenosis after PTA by Cox multivariate analysis
| Variable | Univariate
|
Multivariate
|
||
|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |
| Men | 1.34 (0.98 to 1.84) | 0.065 | ||
| Age | 1.02 (1.01 to 1.05) | 0.0020 | 1.03 (1.01 to 1.05) | 0.0060 |
| Duration of HD | 1.01 (0.95 to 1.03) | 0.51 | ||
| Diabetes | 1.23 (0.87 to 1.73) | 0.23 | ||
| Hypertension | 1.48 (0.98 to 2.21) | 0.056 | ||
| Hyperlipidemia | 1.16 (0.84 to 1.60) | 0.36 | ||
| Smoking | 1.19 (0.86 to 1.65) | 0.28 | ||
| TASC C + D versus A + B | 2.09 (1.54 to 2.85) | 0.0024 | 1.43 (0.93 to 2.21) | 0.10 |
| Femoropopliteal versus iliac | 2.44 (1.60 to 3.72) | <0.0001 | 3.20 (1.67 to 5.13) | 0.0004 |
| Critical limb ischemia | 1.89 (1.25 to 2.86) | <0.0001 | 2.41 (1.53 to 3.82) | 0.0001 |
| Stenting | 0.92 (0.68 to 1.26) | 0.63 | ||
| Cilostazol | 0.55 (0.39 to 0.77) | 0.0005 | 0.56 (0.36 to 0.87) | 0.010 |
| ACE inhibitors | 0.67 (0.46 to 0.99) | 0.046 | 0.62 (0.36 to 1.07) | 0.085 |
| A-II receptor blockers | 0.60 (0.41 to 0.88) | 0.0089 | 0.98 (0.57 to 1.67) | 0.94 |
| β -blockers | 0.77 (0.52 to 1.14) | 0.19 | ||
| Calcium antagonists | 0.71 (0.52 to 0.98) | 0.039 | 0.98 (0.60 to 1.60) | 0.94 |
| Statins | 0.73 (0.51 to 1.05) | 0.090 | ||
| Warfarin | 0.53 (0.19 to 1.43) | 0.21 | ||
| Ticlopidine | 0.66 (0.48 to 0.91) | 0.010 | 0.81 (0.54 to 1.21) | 0.30 |
| Sarpogrelate | 0.70 (0.42 to 1.15) | 0.16 | ||
CI, confidence interval.